Abstract
Prader-Willi syndrome (PWS) is a rare genetic syndrome. The phenotype includes moderate to intellectual disability, dysmorphia, obesity, and behavioral disturbances (e.g., hetero and self-injurious behaviors, hyperphagia, psychosis). Psychotropic medications are widely prescribed in PWS for symptomatic control. We conducted a systematic review of published literature to examine psychotropic medications used in PWS. MEDLINE was searched to identify articles published between January 1967 and December 2014 using key words related to pharmacological treatments and PWS. Articles with original data were included based on a standardized four-step selection process. The identification of studies led to 241 records. All selected articles were evaluated for case descriptions (PWS and behavioral signs) and treatment (type, titration, efficiency, and side effects). Overall, 102 patients were included in these studies. Treatment involved risperidone (three reports, n = 11 patients), fluoxetine (five/n = 6), naltrexone (two/n = 2), topiramate (two/n = 16), fluvoxamine (one/n = 1), mazindol (one/n = 2), N-acetyl cysteine (one/n = 35), rimonabant (one/n = 15), and fenfluramine (one/n = 15).
Conclusion: We identified promising treatment effects with topiramate for self-injury and impulsive/aggressive behaviors, risperidone for psychotic symptoms associated with uniparental disomy (UPD), and N-acetyl cysteine for skin picking. The pharmacological approach of behavioral impairment in PWS has been poorly investigated to date. Further randomized controlled studies are warranted.
What is Known: • Behavioral disturbances in Prader-Willi syndrome including aggressive reactions, skin picking, and hyperphagia might be very difficult to manage. • Antipsychotic drugs are widely prescribed, but weight gain and increased appetite are their major side effects. |
What is New: • Topiramate might be efficient for self-injury and impulsive/aggressive behaviors, N-acetyl cysteine is apromising treatment for skin picking and Antidepressants are indicated for OCD symptoms. • Risperidone is indicated in case of psychotic symptoms mainly associated with uniparental disomy. |
Similar content being viewed by others
Abbreviations
- ABC:
-
Aberrant behavior checklist
- CBT:
-
Cognitive behavioral therapy
- CGI:
-
Clinical global impression
- DEL:
-
Deletion
- OCD:
-
Obsessive compulsive behavior
- ROAS:
-
Retrospective overt aggressive score
- SIRCL:
-
Self-injury restraint checklist
- UPD:
-
Uniparental disomy
- YBC-OC:
-
Yale Brown obsessive compulsive subscale
References
Adams S, Penton-Voak IS, Harmer CJ, Holmes EA, Munafo MR (2013) Effects of emotion recognition training on mood among individuals with high levels of depressive symptoms: study protocol for a randomised controlled trial. Trials 14:161. doi:10.1186/1745-6215-14-161
Amrouche-Mekkioui I, Djerdjouri B (2012) N-acetylcysteine improves redox status, mitochondrial dysfunction, mucin-depleted crypts and epithelial hyperplasia in dextran sulfate sodium-induced oxidative colitis in mice. Eur J Pharmacol 691:209–217. doi:10.1016/j.ejphar.2012.06.014
Araki S, Ohji T, Shiota N, Dobashi K, Shimono M, Shirahata A (2010) Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome. Pediatrics international : official journal of the Japan Pediatric Society 52:e1–e3. doi:10.1111/j.1442-200X.2009.02996.x
Arbaizar B, Gomez-Acebo I, Llorca J (2008) Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry 30:471–475
Banga A, Connor DF (2012) Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome. J Child Adolesc Psychopharmacol 22:396–398. doi:10.1089/cap.2012.0028
Beardsmore A, Dorman T, Cooper SA, Webb T (1998) Affective psychosis and Prader-Willi syndrome. J Intellect Disabil Res 42(Pt 6):463–471
Benarroch F, Hirsch HJ, Genstil L, Landau YE, Gross-Tsur V (2007) Prader-Willi syndrome: medical prevention and behavioral challenges. Child Adolesc Psychiatr Clin N Am 16:695–708. doi:10.1016/j.chc.2007.03.007
Benjamin E, Buot-Smith T (1993) Naltrexone and fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 32:870–873. doi:10.1097/00004583-199307000-00025
Bertella L, Girelli L, Grugni G, Marchi S, Molinari E, Semenza C (2005) Mathematical skills in Prader-Willi Syndrome. J Intellect Disabil Res 49:159–169
Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366:237–248. doi:10.1016/S0140-6736(05)66915-2
Boer H, Holland A, Whittington J, Butler J, Webb T, Clarke D (2002) Psychotic illness in people with Prader Willi syndrome due to chromosome 15 maternal uniparental disomy. Lancet 359:135–136
Buiting K (2010) Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C: Semin Med Genet 154C:365–376. doi:10.1002/ajmg.c.30273
Butler MG, Smith BK, Lee J, Gibson C, Schmoll C, Moore WV, Donnelly JE (2013) Effects of growth hormone treatment in adults with Prader-Willi syndrome. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 23:81–87. doi:10.1016/j.ghir.2013.01.001
Clarke D (1998) Prader-Willi syndrome and psychotic symptoms: 2. A preliminary study of prevalence using the Psychopathology Assessment Schedule for Adults with Developmental Disability checklist. J Intellect Disabil Res 42(Pt 6):451–454
Deb S, Unwin G, Deb T (2014) Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. J Intellect Disabil Res. doi:10.1111/jir.12119
Dech B, Budow L (1991) The use of fluoxetine in an adolescent with Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 30:298–302. doi:10.1097/00004583-199103000-00020
Dolengevich Segal H, Rodriguez Salgado B, Conejo Garcia A, San Sebastian Cabases J (2006) Efficacy of topiramate in children and adolescent with problems in impulse control: preliminary results. Actas Esp Psiquiatr 34:280–282
Duggan L, Brylewski J (1999) Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review. J Intellect Disabil Res 43(Pt 2):94–104
Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J (2000) Risperidone in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 39:545–546. doi:10.1097/00004583-200005000-00004
Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J (2000) Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatr Scand 102:461–465
Dykens EM, Roof E (2008) Behavior in Prader-Willi syndrome: relationship to genetic subtypes and age. J Child Psychol Psychiatry 49:1001–1008
Fieldstone A, Zipf WB, Sarter MF, Berntson GG (1998) Food intake in Prader-Willi syndrome and controls with obesity after administration of a benzodiazepine receptor agonist. Obes Res 6:29–33
Francey SM, Nelson B, Thompson A, Parker AG, Kerr M, Macneil C, Fraser R, Hughes F, Crisp K, Harrigan S, Wood SJ, Berk M, McGorry PD (2010) Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res 119:1–10
Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M, speakers contributors at the Second Expert Meeting of the Comprehensive Care of Patients with PWS (2008) Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 93:4183–4197. doi:10.1210/jc.2008-0649
Hassler F, Reis O (2010) Pharmacotherapy of disruptive behavior in mentally retarded subjects: a review of the current literature. Dev Disabil Res Rev 16:265–272. doi:10.1002/ddrr.119
Herguner S, Mukaddes NM (2007) Psychosis associated with fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 46:944–945. doi:10.1097/chi.0b013e318068fbed
Itoh M, Koeda T, Ohno K, Takeshita K (1995) Effects of mazindol in two patients with Prader-Willi syndrome. Pediatr Neurol 13:349–351
Jauregi J, Arias C, Vegas O, Alen F, Martinez S, Copet P, Thuilleaux D (2007) A neuropsychological assessment of frontal cognitive functions in Prader-Willi syndrome. J Intellect Disabil Res 51:350–365
Kennedy GM, Lhatoo SD (2008) CNS adverse events associated with antiepileptic drugs. CNS Drugs 22:739–760
Khan A, Faught E, Gilliam F, Kuzniecky R (1999) Acute psychotic symptoms induced by topiramate. Seizure 8:235–237
Kohn Y, Weizman A, Apter A (2001) Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine. Int J Eat Disord 30:113–117
Kyriakides M, Silverstone T, Jeffcoate W, Laurance B (1980) Effect of naloxone on hyperphagia in Prader-Willi syndrome. Lancet 1:876–877
Lee YJ, Marcu S, Berall G, Shapiro CM (2011) Tryptophan for the treatment of excessive daytime sleepiness in Prader-Willi syndrome. Indian Pediatr 48:319–321
Lin G, Lawrence R (2006) Pediatric case report of topiramate toxicity. Clin Toxicol (Phila) 44:67–69
Matthews SC, Miller BP (2001) Auditory hallucinations associated with topiramate. J Clin Psychiatry 62:653
Miller JL, Angulo M (2014) An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A 164:421–424. doi:10.1002/ajmg.a.36306
Morgan JR, Storch EA, Woods DW, Bodzin D, Lewin AB, Murphy TK (2010) A preliminary analysis of the phenomenology of skin-picking in Prader-Willi syndrome. Child Psychiatry Hum Dev 41:448–463. doi:10.1007/s10578-010-0180-7
Motaghedi R, Lipman EG, Hogg JE, Christos PJ, Vogiatzi MG, Angulo MA (2011) Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome. Eur J Med Genet 54:14–18. doi:10.1016/j.ejmg.2010.09.015
Mula M, Trimble MR, Lhatoo SD, Sander JW (2003) Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44:659–663
Orphanet (2013) Prevalence of rare diseases. http://www.orpha.net/orphacom/cahiers/docs/FR/Prevalence_des_maladies_rares_par_prevalence_decroissante_ou_cas.pdf. Accessed January 2014
Rana F, Gormez A, Varghese S (2013) Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities. The Cochrane database of systematic reviews 4:CD009084. doi:10.1002/14651858.CD009084.pub2
Reas DL, Grilo CM (2008) Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring) 16:2024–2038
Reis AD, Castro LA, Faria R, Laranjeira R (2008) Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 30:132–135
Schepis C, Failla P, Siragusa M, Palazzo R, Romano C (1998) Failure of fluoxetine to modify the skin-picking behaviour of Prader-Willi syndrome. Australas J Dermatol 39:57–58
Selikowitz M, Sunman J, Pendergast A, Wright S (1990) Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial. Arch Dis Child 65:112–114
Semenza C, Pignatti R, Bertella L, Ceriani F, Mori I, Molinari E, Giardino D, Malvestiti F, Grugni G (2008) Genetics and mathematics: evidence from Prader-Willi syndrome. Neuropsychologia 46:206–212
Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ (2004) Effects of topiramate in adults with Prader-Willi syndrome. American journal of mental retardation : AJMR 109:301–309. doi:10.1352/0895-8017(2004)109<301:EOTIAW>2.0.CO;2
Shapira NA, Lessig MC, Murphy TK, Driscoll DJ, Goodman WK (2002) Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 5:141–145. doi:10.1017/S1461145702002833
Sinnema M, Boer H, Collin P, Maaskant MA, van Roozendaal KE, Schrander-Stumpel CT, Curfs LM (2011) Psychiatric illness in a cohort of adults with Prader-Willi syndrome. Res Dev Disabil 32:1729–1735. doi:10.1016/j.ridd.2011.02.027
Skokauskas N, Sweeny E, Meehan J, Gallagher L (2012) Mental health problems in children with prader-willi syndrome. Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l’Academie canadienne de psychiatrie de l’enfant et de l’adolescent 21:194–203
Smathers SA, Wilson JG, Nigro MA (2003) Topiramate effectiveness in Prader-Willi syndrome. Pediatr Neurol 28:130–133
Soni S, Whittington J, Holland AJ, Webb T, Maina E, Boer H, Clarke D (2007) The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment. J Intellect Disabil Res 51:32–42. doi:10.1111/j.1365-2788.2006.00895.x
Soni S, Whittington J, Holland AJ, Webb T, Maina EN, Boer H, Clarke D (2008) The phenomenology and diagnosis of psychiatric illness in people with Prader-Willi syndrome. Psychol Med 38:1505–1514
Stella F, Caetano D, Cendes F, Guerreiro CA (2002) Acute psychotic disorders induced by topiramate: report of two cases. Arq Neuropsiquiatr 60:285–287
Unwin GL, Deb S (2011) Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: a systematic review. Res Dev Disabil 32:2121–2133. doi:10.1016/j.ridd.2011.07.031
Van Borsel J, Defloor T, Curfs LM (2007) Expressive language in persons with Prader-Willi syndrome. Genet Couns 18:17–28
Vogels A, Matthijs G, Legius E, Devriendt K, Fryns JP (2003) Chromosome 15 maternal uniparental disomy and psychosis in Prader-Willi syndrome. J Med Genet 40:72–73
Whitman BY, Accardo P (1987) Emotional symptoms in Prader-Willi syndrome adolescents. Am J Med Genet 28:897–905
Whittington J, Holland A, Webb T, Butler J, Clarke D, Boer H (2004) Academic underachievement by people with Prader-Willi syndrome. J Intellect Disabil Res 48:188–200
Wu K, Hanna GL, Easter P, Kennedy JL, Rosenberg DR, Arnold PD (2013) Glutamate system genes and brain volume alterations in pediatric obsessive-compulsive disorder: a preliminary study. Psychiatry Res 211:214–220. doi:10.1016/j.pscychresns.2012.07.003
Authors’ contribution
OB, DC, and MT conceived of the study and participated in its design and coordination and helped to draft the manuscript. DC made the most important contribution to this second part. All authors (OB, DC, AC, SC, DT, and MT) did participate in the meetings regarding the bibliography search, the reading of the selected articles, and the related discussions. OB, DC, DT, and MT participated in the design of the study. All authors read and approved the final manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Research is not involving human participant.
This article does not contain any studies with human participant performed by any of the authors. There is no human or animal material use in this study and no personal data of any kind. Our work is entirely based on literature search.
Informed consent
Informed consent was not relevant. No informed consent.
Conflict of interest
The authors declare that they have no competing interests.
Funding
This study was funded by a Grant of French Ministry of Health (PHRC 2010-AOM1008).
Information’s regarding authors
We are a group of psychiatrists and pediatrician implicated in rare disease with psychiatric symptoms, including PWS. We are working in a national reference network in this field funded by the French government and European Union. MT, DT, and SC are working in the National Reference Center for PWS, and OB, DC, and AC are working in the National Reference Center for Psychiatric Symptoms of Rare Disease.
Additional information
Communicated by Jaan Toelen
Rights and permissions
About this article
Cite this article
Bonnot, O., Cohen, D., Thuilleaux, D. et al. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature. Eur J Pediatr 175, 9–18 (2016). https://doi.org/10.1007/s00431-015-2670-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-015-2670-x